Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment

Acute myeloid leukemia (AML) treatment has always been a challenge to the treating physician. Continuous efforts are being made to improve treatment outcomes in AML. CPX-351 is a pharmacologic advancement in this direction. It is a liposomal fixed drug combination of cytarabine and daunorubicin. Ear...

Descripción completa

Detalles Bibliográficos
Autor principal: Raut, Lalit S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Drug Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382783/
https://www.ncbi.nlm.nih.gov/pubmed/25839020
http://dx.doi.org/10.4103/2278-330X.149950
_version_ 1782364632947621888
author Raut, Lalit S.
author_facet Raut, Lalit S.
author_sort Raut, Lalit S.
collection PubMed
description Acute myeloid leukemia (AML) treatment has always been a challenge to the treating physician. Continuous efforts are being made to improve treatment outcomes in AML. CPX-351 is a pharmacologic advancement in this direction. It is a liposomal fixed drug combination of cytarabine and daunorubicin. Early studies indicate that it will play a big role in AML treatment. This is a short review about this drug.
format Online
Article
Text
id pubmed-4382783
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-43827832015-04-02 Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment Raut, Lalit S. South Asian J Cancer Drug Review Acute myeloid leukemia (AML) treatment has always been a challenge to the treating physician. Continuous efforts are being made to improve treatment outcomes in AML. CPX-351 is a pharmacologic advancement in this direction. It is a liposomal fixed drug combination of cytarabine and daunorubicin. Early studies indicate that it will play a big role in AML treatment. This is a short review about this drug. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4382783/ /pubmed/25839020 http://dx.doi.org/10.4103/2278-330X.149950 Text en Copyright: © South Asian Journal of Cancer http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Drug Review
Raut, Lalit S.
Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
title Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
title_full Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
title_fullStr Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
title_full_unstemmed Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
title_short Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
title_sort novel formulation of cytarabine and daunorubicin: a new hope in aml treatment
topic Drug Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382783/
https://www.ncbi.nlm.nih.gov/pubmed/25839020
http://dx.doi.org/10.4103/2278-330X.149950
work_keys_str_mv AT rautlalits novelformulationofcytarabineanddaunorubicinanewhopeinamltreatment

Ejemplares similares